Compare ACLS & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACLS | IRTC |
|---|---|---|
| Founded | 1995 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | 2000 | 2016 |
| Metric | ACLS | IRTC |
|---|---|---|
| Price | $131.51 | $111.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $101.50 | ★ $197.92 |
| AVG Volume (30 Days) | 559.0K | ★ 620.1K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $839,048,000.00 | $747,138,000.00 |
| Revenue This Year | $1.93 | $19.60 |
| Revenue Next Year | $7.91 | $15.94 |
| P/E Ratio | $452.03 | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $65.64 | $100.85 |
| 52 Week High | $193.78 | $210.01 |
| Indicator | ACLS | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 38.99 | 43.55 |
| Support Level | $130.15 | $111.37 |
| Resistance Level | $147.94 | $121.88 |
| Average True Range (ATR) | 10.93 | 5.67 |
| MACD | -2.55 | -1.16 |
| Stochastic Oscillator | 12.75 | 14.54 |
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.